Abstract
▴ Fenofibric acid activates peroxisome proliferator-activated receptor α to modify fatty acid and lipid metabolism. Fenofibric acid is the first member of the fibric acid derivatives (fibrates) class approved for use as combination therapy with HMG-CoA reductase inhibitors (statins).
▴ In three randomized, double-blind, multicenter, phase III trials in adult patients with mixed dyslipidemia, up to 12 weeks’ treatment with once-daily fenofibric acid 135 mg plus a low- or moderate-dose statin (atorvastatin 20 or 40 mg, rosuvastatin 10 or 20 mg, or simvastatin 20 or 40 mg) improved high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels to a significantly greater extent than statin monotherapy, and improved low-density lipoprotein cholesterol (LDL-C) levels to a significantly greater extent than fenofibric acid monotherapy.
▴ In a 52-week, open-label, multicenter, extension study, HDL-C, TG, and LDL-C levels continued to improve, or were maintained, during combination therapy with once-daily fenofibric acid 135 mg plus a moderate-dose statin (atorvastatin 40 mg, rosuvastatin 20 mg, or simvastatin 40 mg).
▴ Once-daily fenofibric acid 135 mg plus a statin was generally as well tolerated as monotherapy with fenofibric acid 135 mg/day or the corresponding statin dosage in the three phase III trials in patients with mixed dyslipidemia. The incidence of adverse events was similar between the combination therapy group and both monotherapy groups.
▴ In the extension trial, once-daily fenofibric acid 135 mg plus a moderate-dose statin (atorvastatin 40 mg, rosuvastatin 20 mg, or simvastatin 40 mg) for up to 52 weeks was generally well tolerated.
Similar content being viewed by others
References
National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002 Dec 17; 106(25): 3143–421.
Cheung BMY, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009 May; 122(5): 443–53.
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004 Oct; 27(10): 2444–9.
British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 Dec; 91 Suppl. 5: v1–52.
Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther 2008 Feb; 30(2): 294–306.
Quilliam BJ, Perez HE, Andros V, et al. Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. J Manag Care Pharm 2004 May–Jun; 10(3): 244–50.
Rajagopalan S, Alemao E, Finch L, et al. Impact of new Joint British Society’s (JBS 2) guidelines on prevention of cardiovascular disease: evaluation of serum total cholesterol goal achievement in UK clinical practice. Curr Med Res Opin 2007 Aug; 23(8): 2027–34.
Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs 2008 Oct; 17(10): 1599–614.
Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67(1): 121–53.
US FDA. Trilipix (fenofibric acid) oral delayed release capsules: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022224s000lbl.pdf [Accessed 2009 Oct 20].
Abbott Laboratories. Frequently asked questions about TRILIPIX [online]. Available from URL: http://www.trilipix.com/AboutTrilipix/FAQs.aspx [Accessed 2009 Oct 20].
Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62(13): 1909–44.
Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiol Rev 2005 Sep–Oct; 13(5): 240–6.
Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPARα): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009 Jul; 205(1): 1–8.
Zhu T, Awni WM, Hosmane B, et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol 2009 Jan; 49(1): 63–71.
Abbott Laboratories. Tricor (fenofibrate tablets): US prescribing information [online]. Available from URL: http://www.rxabbott.com/pdf/tricorpi.pdf [Accessed 2009 Oct 20].
Tojcic J, Benoit-Biancamano MO, Court MH, et al. In vitro glucuronidation of fenofibric acid by human UGTs and liver microsomes. Drug Metab Dispos 2009 Nov; 37(11): 2236–43.
Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009 Feb 15; 103(4): 515–22.
Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009 May; 204(1): 208–15.
Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009 Jan; 157(1): 195–203.
Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Invest 2008; 28(10): 625–34.
Bays HE, Jones PH, Mohiuddin M, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008 Dec; 2(6): 426–35.
Jones PH, Davidson MH, Goldberg AC, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidol 2009 Apr; 3(2): 125–37.
Goldberg AC, Robinson JG, Pepine CJ, et al. Fenofibricacidincombination with statins improves multiple lipid parameters in women with mixed dyslipidemia [abstract no. 1012-85]. J Am Coll Cardiol 2009 Mar 10; 53 Suppl. 1 (10): A202.
Sleep DJ, Goldberg AC, Setze CM, et al. Efficacy of fenofibric acid in combination with atorvastatin in patients with type 2 diabetes mellitus and mixed dyslipidaemia [abstract no. 1248]. 45th Annual Meeting of the European Association for the Study of Diabetes; 2009 Sep 30; Vienna.
Rosenson RS, Carlson DM, Kelly MT, et al. Simultaneous attainment of lipid targets with the combination of fenofibric acid and rosuvastatin in patients with type 2 diabetes mellitus [abstract no. 936-P]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5–9; New Orleans (LA).
Acknowledgments and Disclosures
The manuscript was reviewed by: P.R. Devchand, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA; R. Guthrie Department of Emergency Medicine, Ohio State University, Columbus, Ohio, USA; S.J. Nicholls, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, L.P.H., Keating, G.M. Fenofibric Acid. Am J Cardiovasc Drugs 9, 401–409 (2009). https://doi.org/10.2165/11203920-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11203920-000000000-00000